Agreed, even if the virus is getting less lethal t
Post# of 154804
(Total Views: 587)
Posted On: 06/02/2020 6:23:32 AM
Agreed, even if the virus is getting less lethal there is plenty of need, but time is of the essence for a number of reasons, this included...funny thing is some see this viral weakness/change data as anecdotal...I say you can't have it both ways when convenient to ones cause.
I am convinced type 1 control can be improved by several days of fasting using the FMD diet. It is a quantum leap of faith to not eat and cut/reduce insulin but it works for me at least once per month, my a1c tests have never been better. Your link to the article on resveratrol and curcumin was interesting because I take both.
The start and reversal of type 1 is also being trialed in the gut microbiome with an easy-to-take capsule (AG019) consisting of engineered Lactococcus lactis specifically modified to deliver human proinsulin and the tolerance-enhancing cytokine human interleukin-10 to the mucosal lining of the gastro-intestinal tissues. The microbe-based platform offers several advantages over injectable biologics including a unique delivery method of a therapeutic agent capable of inducing oral immune tolerance to reverse T1D. And in trials/conjunction with another mAb called teplizumab (anti-CD3) where regulatory cytokines are released and regulatory T cells are expanded that may lead to the reestablishment of immune tolerance.
I am convinced type 1 control can be improved by several days of fasting using the FMD diet. It is a quantum leap of faith to not eat and cut/reduce insulin but it works for me at least once per month, my a1c tests have never been better. Your link to the article on resveratrol and curcumin was interesting because I take both.
The start and reversal of type 1 is also being trialed in the gut microbiome with an easy-to-take capsule (AG019) consisting of engineered Lactococcus lactis specifically modified to deliver human proinsulin and the tolerance-enhancing cytokine human interleukin-10 to the mucosal lining of the gastro-intestinal tissues. The microbe-based platform offers several advantages over injectable biologics including a unique delivery method of a therapeutic agent capable of inducing oral immune tolerance to reverse T1D. And in trials/conjunction with another mAb called teplizumab (anti-CD3) where regulatory cytokines are released and regulatory T cells are expanded that may lead to the reestablishment of immune tolerance.
(1)
(0)